June 11, 2013 Gokce Simsek, MD; Cem Saka, MD; Didem N. Sonbay, MD; Istemihan Akin, MD; and Fulya Koybasioglu, MD
article
Abstract
Aneurysmal bone cyst is a benign and locally destructive bone lesion usually seen in the younger population. Its etiology is unknown. Its yearly incidence rate has been reported to be 0.14/100,000, comprising 1% of all bone tumors. It may develop primarily or arise from primary bone tumors. Hemorrhagic fluid content with a septated appearance is the characteristic feature of aneurysmal bone cyst. It is most commonly seen in the metaphysis of the long bones. In rare cases, the cyst is located in the skull. Primary treatment is surgical excision, and the recurrence rate after treatment is 10 to 30%. Based on a review of the current literature, there have been no previous reports of aneurysmal bone cyst located in the middle turbinate. We report a case of aneurysmal bone cyst with an atypical location and discuss the treatment of the patient with endoscopic surgery in light of relevant literature.
April 17, 2013 Samar Pal Singh Yadav, MS(ORL); Joginder Singh Gulia, MS(ORL); Anita Hooda, MDS(Prosthodontics); Ajoy Kumar Khaowas, MS
article
Abstract
Osteoma of the nose is a slowly developing benign tumor with a reported incidence of 0.6% of all the osteomas of the nose and paranasal sinuses. It is asymptomatic in initial stages and is usually diagnosed when it causes nasal obstruction. Osteoma arising from the middle turbinate is very rare and only two cases have been previously reported. We report a giant middle turbinate measuring 36 x 35 x 20 mm which, to the best of our knowledge, is the largest reported osteoma arising from the middle turbinate.
October 4, 2012 Pradipta K. Parida, MS, DNB; Ramandeep Singh Virk, MS;
article
Abstract
Meningioma of the sinonasal tract is a rare entity. Meningioma of the nose and paranasal sinuses may occur in one of two ways: (1) by secondary extension of a primary tumor in the cranial cavity or orbit or (2) primarily in the nose and paranasal sinuses de novo from the ectopic meningocytes derived from pluripotent mesenchymal cells. Primary sinonasal meningiomas are often difficult to diagnose because of their infrequent occurrence. The final diagnosis rests on the histologic examination. We report what is to our knowledge the first case of primary meningioma of the middle turbinate.
June 4, 2012 Dewey A. Christmas, MD; Joseph P. Mirante, MD, FACS; Eiji Yanagisawa, MD, FACS
article
Compensatory hypertrophy of the middle turbinate can occur when a patient's nasal septum is markedly deflected to one side, enlarging the airway and hence giving the middle turbinate an unusually large space in which to expand.
April 30, 2012 Rabia Shihada, MD; Michal Luntz, MD
article
Abstract
A concha bullosa is a common anatomic variant that represents an aerated turbinate, usually the middle turbinate. It is usually asymptomatic. When extensively pneumatized, a large concha bullosa may cause significant problems, including headache, nasal obstruction, and blockage of sinus drainage. We report a case of a large concha bullosa mucopyocele that manifested as recurring migraine headaches. It was successfully treated with surgical excision. We also review the available literature.
October 26, 2011 Senol Polat, MD, Hasan Murat Tanyeri, MD, and Selcuk Bilgi, MD
article
Abstract
Inferior turbinate reduction by radiofrequency ablation (RFA) has been recommended as an easy and safe option for the treatment of patients with inferior turbinate hypertrophy. Complications of this type of excision are generally acceptable. We describe a case of RFA turbinate reduction that resulted in an unusual complication: the formation of an arteriovenous hemangioma.
September 20, 2011 Jae Hoon Lee, MD and Seung Hyun Koh, MD
December 17, 2010 Dewey A. Christmas, MD, Joseph P. Mirante, MD, FACS, and Eiji Yanagisawa, MD, FACS
October 31, 2010 Dewey A. Christmas, MD, Joseph P. Mirante, MD, FACS, and Eiji Yanagisawa, MD, FACS
October 31, 2010 Dong-Hee Lee, MD, PhD and Eun Hye Kim, MD
article
Abstract
A case-control study was conducted at our secondary referral hospital to compare the efficacy of microdebrider-assisted turbinate reduction (MATR) with laser-assisted turbinate reduction (LATR) and to evaluate their efficacy according to types of hypertrophic inferior turbinates. All patients who underwent only inferior turbinate surgery for refractory nasal obstruction were included. The required minimum follow-up period was 3 months postoperatively. Thirty-seven patients were enrolled in this study-22 in the MATR group and 15 in the LATR group. The patients were subclassified into mucosal (n = 14) and bone (n = 23) hypertrophy groups. Subjective (visual analogue scale) and objective (endoscopic score) assessments were performed prior to surgery and 3 months after surgery. Generally, the visual analogue scale and endoscopic score were significantly improved after surgery, in both the MATR and the LATR groups. In the MATR group, the visual analogue scale and endoscopic score improved regardless of type of hypertrophy. However, in the LATR group, these measurements improved only in cases with mucosal hypertrophy. We conclude that both MATR and LATR are good surgical techniques in patients with chronic hypertrophic inferior turbinates who have substantial nasal obstruction. However, MATR is superior to LATR, especially in cases with bone hypertrophy.
April 30, 2010 Borlingegowda Viswanatha, MS, DLO
article
Abstract
Osteomas of the turbinates are extremely rare. In this report, a case of inferior turbinate osteoma in a 24-year-old woman is described. The patient presented with a 6-month history of unilateral nasal obstruction. Computed tomography showed a bony dense mass in the anterior part of the left inferior turbinate. The lesion was removed endoscopically, and the patient recovered uneventfully. To the best of the author's knowledge, this is only the fifth case of a turbinate osteoma to be reported in the world literature, and only the second case that involved the inferior turbinate.
March 31, 2010 Dewey A. Christmas, MD, Joseph P. Mirante, MD, FACS, and Eiji Yanagisawa, MD, FACS
